BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9733270)

  • 1. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.
    Millar BC; Millar JL; Shepherd V; Blackwell P; Porter H; Cunningham D; Judson I; Treleaven J; Powles RL; Catovsky D
    Bone Marrow Transplant; 1998 Sep; 22(5):469-75. PubMed ID: 9733270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.
    Millar BC; Millar JL; Bell JB; Raje N; Milan S; Mehta J; Singhal S; Middleton GW; Sheperd V; Catovsky D; Powles RL
    Bone Marrow Transplant; 1996 Nov; 18(5):871-8. PubMed ID: 8932839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.
    Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE
    Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant.
    Maharaj D; Steinberg JP; Gouvea JV; Gieser PW
    Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation.
    Watanabe T; Dave B; Heimann DG; Jackson JD; Kessinger A; Talmadge JE
    Exp Hematol; 1998 Jan; 26(1):10-8. PubMed ID: 9430509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients.
    Specchia G; Pastore D; Mestice A; Liso A; Carluccio P; Leo M; Casanova M; Sibilla S; Giannoccaro M; Liso V
    Acta Haematol; 2006; 116(4):229-37. PubMed ID: 17119322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience.
    Lowenthal RM; Fabères C; Marit G; Boiron JM; Cony-Makhoul P; Pigneux A; Agape P; Vezon G; Bouzgarou R; Dazey B; Fizet D; Bernard P; Lacombe F; Reiffers J
    Bone Marrow Transplant; 1998 Oct; 22(8):763-70. PubMed ID: 9827973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation.
    Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED
    Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of infused CFU-GM and CFU-Mk mobilized by chemotherapy with or without G-CSF to platelet recovery after autologous blood stem cell transplantation.
    Takamatsu Y; Harada M; Teshima T; Makino S; Inaba S; Akashi K; Shibuya T; Niho Y
    Exp Hematol; 1995 Jan; 23(1):8-13. PubMed ID: 7527786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant.
    Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ
    Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients.
    Gandhi MK; Jestice K; Scott MA; Bloxham D; Bass G; Marcus RE
    Bone Marrow Transplant; 1999 Jan; 23(1):9-13. PubMed ID: 10037044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.